AZ/Merck & Co' s Lynparza Gets US Approval For Prostate Cancer
Days After Green Light For Clovis's Rival PARP
Executive Summary
Lynparza has received the green light from the FDA for advanced prostate cancer, its fourth tumor type, and while it may not be the first PARP inhibitor to be approved for this indication, analysts are expecting the drug to lead the class.
You may also be interested in...
AstraZeneca’s Lynparza Adds Narrow Prostate Cancer Indication
AstraZeneca had hoped data from Phase III PROpel would lead to an all-comers indication in first-line, metastatic castration-resistant prostate cancer, but new indication is limited to BRCA mutations.
AstraZeneca Partners With AmoyDx On Companion Diagnostics For Lynparza
Teaming again with the Shanghai biotech, AstraZeneca will seek assays that can be incorporated into companion diagnostics for Lynparza in prostate and breast cancer.
AstraZeneca Partners With AmoyDx On Companion Diagnostics For Lynparza
Deal Snapshot: Teaming again with the Shanghai biotech, AstraZeneca will seek assays that can be incorporated into companion diagnostics for Lynparza in prostate and breast cancer.